Noah Rosenberg takes chief medical officer role at Esperion

Will develop and manage the firm’s clinical programmes

Noah Rosenberg has taken over as chief medical officer (CMO) at Esperion Therapeutics and will lead the Esperion clinical advisory board and develop and manage the company's clinical programmes. He will also manage the regulatory review process for the company's investigational therapies to treat cardiovascular and metabolic diseases.

Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.

‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Subscribe now